Guggenheim Downgrades BioXcel Therapeutics to Neutral
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Yatin Suneja has downgraded BioXcel Therapeutics from Buy to Neutral.

July 17, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BioXcel Therapeutics has been downgraded from Buy to Neutral by Guggenheim analyst Yatin Suneja.
The downgrade from Buy to Neutral by a Guggenheim analyst indicates a less optimistic outlook for the company's stock. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100